Drug adherence and treatment duration for denosumab and mortality risk among hip fracture patients.

[1]  Ja Hwang,et al.  The Impact of Various Anti‐Osteoporosis Drugs on All‐Cause Mortality After Hip Fractures: A Nationwide Population Study , 2022, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  M. Amling,et al.  Beneficial effect of denosumab on muscle performance in patients with low BMD: A retrospective, propensity score-matched analysis , 2022, Bone Reports.

[3]  D. Kendler,et al.  Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review , 2021, Advances in Therapy.

[4]  Chih-Hsing Wu,et al.  Treatment of osteoporosis after hip fracture is associated with lower all-cause mortality: A nationwide population study. , 2021, Bone.

[5]  M. Chandran,et al.  Adherence to dosing schedule of denosumab therapy for osteoporosis during COVID-19 lockdown: an electronic medical record and pharmacy claims database study from Asia , 2021, Osteoporosis International.

[6]  S. Casimiro,et al.  The Roadmap of RANKL/RANK Pathway in Cancer , 2021, Cells.

[7]  Y. E. Miedany,et al.  Is there a potential dual effect of denosumab for treatment of osteoporosis and sarcopenia? , 2021, Clinical Rheumatology.

[8]  C. Poiană,et al.  Adherence to Anti-Osteoporotic Treatment and Clinical Implications after Hip Fracture: A Systematic Review , 2021, Journal of personalized medicine.

[9]  M. Yavropoulou,et al.  Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review , 2021, Journal of clinical medicine.

[10]  R. Eastell,et al.  Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. , 2020, The Journal of clinical endocrinology and metabolism.

[11]  M. Hiligsmann,et al.  Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review , 2020, Osteoporosis International.

[12]  D. Solomon,et al.  Delayed Denosumab Injections and Bone Mineral Density Response: An Electronic Health Record-based Study. , 2020, The Journal of clinical endocrinology and metabolism.

[13]  T. Cheng,et al.  Adherence to anti-osteoporosis medication associated with lower mortality following hip fracture in older adults: a nationwide propensity score-matched cohort study , 2019, BMC Geriatrics.

[14]  H. Yagita,et al.  An anti-RANKL treatment reduces muscle inflammation and dysfunction and strengthens bone in dystrophic mice. , 2019, Human molecular genetics.

[15]  G. Duque,et al.  Effect of Denosumab on Falls, Muscle Strength, and Function in Community‐Dwelling Older Adults , 2019, Journal of the American Geriatrics Society.

[16]  S. Cummings,et al.  Association Between Drug Treatments for Patients With Osteoporosis and Overall Mortality Rates: A Meta-analysis. , 2019, JAMA internal medicine.

[17]  E. Pérez Fernández,et al.  Mortality after osteoporotic hip fracture: incidence, trends, and associated factors , 2019, Journal of Orthopaedic Surgery and Research.

[18]  Chien-Ning Hsu,et al.  Comparison of the Effects of Denosumab and Alendronate on Cardiovascular and Renal Outcomes in Osteoporotic Patients , 2019, Journal of clinical medicine.

[19]  P. V. van Dam,et al.  RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment. , 2019, Critical reviews in oncology/hematology.

[20]  Y. Kwan,et al.  A systematic review of factors affecting medication adherence among patients with osteoporosis , 2018, Osteoporosis International.

[21]  S. Ozawa,et al.  Denosumab: A Unique Perspective on Adherence and Cost-effectiveness Compared With Oral Bisphosphonates in Osteoporosis Patients , 2018, The Annals of pharmacotherapy.

[22]  R. Queipo,et al.  Baseline and pre-operative 1-year mortality risk factors in a cohort of 509 hip fracture patients consecutively admitted to a co-managed orthogeriatric unit (FONDA Cohort). , 2018, Injury.

[23]  R. Eastell,et al.  Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. , 2017, Bone.

[24]  S. Sánchez-Fidalgo,et al.  Adherence and preference of intravenous zoledronic acid for osteoporosis versus other bisphosphonates , 2017, European journal of hospital pharmacy. Science and practice.

[25]  C. Roux,et al.  Imminent fracture risk , 2017, Osteoporosis International.

[26]  P. Souverein,et al.  Long-term persistence with anti-osteoporosis drugs after fracture , 2015, Osteoporosis International.

[27]  K. Saag,et al.  Fracture mortality: associations with epidemiology and osteoporosis treatment , 2014, Nature Reviews Endocrinology.

[28]  D. Kiel,et al.  RANKL Inhibition With Denosumab Does Not Influence 3‐Year Progression of Aortic Calcification or Incidence of Adverse Cardiovascular Events in Postmenopausal Women With Osteoporosis and High Cardiovascular Risk , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  K. Tsai,et al.  Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan , 2013, Osteoporosis International.

[30]  F. Tarazona-Santabalbina,et al.  Early interdisciplinary hospital intervention for elderly patients with hip fractures – functional outcome and mortality , 2012, Clinics.

[31]  Ho-Shik Kim,et al.  Receptor activator of nuclear factor-κB ligand is a novel inducer of myocardial inflammation. , 2012, Cardiovascular research.

[32]  S. Cummings,et al.  Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. , 2011, The Journal of clinical endocrinology and metabolism.

[33]  P. Kostenuik,et al.  Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. , 2009, The American journal of pathology.

[34]  R. Herings,et al.  Loss of treatment benefit due to low compliance with bisphosphonate therapy , 2007, Osteoporosis International.

[35]  S. Silverman,et al.  Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. , 2006, Mayo Clinic proceedings.

[36]  D. Roy,et al.  How many people develop fractures with what outcome? , 2005, Best practice & research. Clinical rheumatology.

[37]  J. Avorn,et al.  Compliance with osteoporosis medications. , 2005, Archives of internal medicine.

[38]  G. Dinant,et al.  Risk of new clinical fractures within 2 years following a fracture , 2005, Osteoporosis International.